Other functions - preclinical in vitro and in vivo agent development assays
Ended Awarded Last action
- Contract number
- HHSN261201200021I
- Awardee
-
University Of Alabama At Birmingham UEI YND4PLMC9AN7
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Task orders
- 7 $3,317,848 obligated
Award facts
- Combined order value
- $3,317,848 Current and potential, with all options
- Last date to order 100% complete
- Maximum order
- $9,900,000.00
- Award type
- Multiple award
- Who can order
- Only the awarding agency
- NAICS code
- 541711 Research and Development in Biotechnology
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 5 offers Negotiated Proposal / Quote
- Pricing
- Order Dependent (IDV only)
Award details come from SAM.gov/FPDS.
About this IDV
The federal contract IDV award was issued by the National Cancer Institute (NCI) for "Preclinical In Vitro and In Vivo Agent Development Assays" with a ceiling value of $0. The multiple-award IDC has a parent master IDIQ contract titled "Preclinical Agent Development Assays 2012-2016" and was awarded to the University of Alabama at Birmingham (UAB) on September 20, 2012, with an ultimate completion date of September 19, 2014.
Under this IDC, UAB has been issued several cost-reimbursement and firm-fixed-price task orders to conduct various preclinical research studies in support of NCI's cancer drug development efforts. The total value of the individual task orders ranges from $2,329 to $789,050, with work performed at UAB's facilities in Birmingham, Alabama. The task orders involve evaluating the efficacy of therapeutic agents, including bazedoxifene, pioglitazone/metformin, and a multi-antigen vaccine, in preventing mammary cancers in animal models. The research efforts also assess the impact of different dietary regimens, such as standard chow, high-fat, and high-fructose diets, on the chemopreventive effects of the tested agents.
Task orders
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Original award | $0 |
Quick answers
Who was awarded contract HHSN261201200021I?
HHSN261201200021I was awarded to University Of Alabama At Birmingham by National Cancer Institute (National Institutes of Health) on September 20, 2012.
How much is contract HHSN261201200021I worth?
Orders under HHSN261201200021I have obligated $3,317,848. A single order can be worth up to $9,900,000.
How many orders have been placed under contract HHSN261201200021I?
7 orders have been placed under HHSN261201200021I, the latest on September 12, 2014.
Who can order from contract HHSN261201200021I?
HHSN261201200021I is a multiple award indefinite delivery contract. Only the awarding agency can place orders on it.
Is contract HHSN261201200021I part of a contract vehicle?
Yes. HHSN261201200021I is part of Preclinical Agent Development Assays 2012-2016.
Was contract HHSN261201200021I competed?
The extent of competition for HHSN261201200021I was full and open competition. The government received 5 offers.
On GovTribe
See this IDV's full record
- Every order and transaction
- The awardee's other awards and teaming partners
- Similar IDVs and recompete opportunities
- Ask GovTribe AI about this IDV